[Therapeutic effect of dopaminergic substances in drug-resistant Lennox-Gastaut syndrome].
The authors administered to 18 children with an expressed pharmaco-resistant Lennox-Gastaut syndrome as adjuvant treatment medium doses of amantadine (Viregyt-K, Egyt), 8 mg/kg/day divided into 1-2 portions or L-DOPA (Nakom, Lek) 22 mg/kg/day in 3-4 portions. The mean age at the time of administration of the agonist or dopamine precursor was 5 years (1-12.5 years). A very favourable clinical effect was recorded in eight children, in another five the positive effect was less obvious and was transient. Only in five instances the paroxysmal manifestations were not affected. Reduction of the EEG pathology corresponded to the clinical improvement. In 11 children the psychic make-up was favourably influenced and only once polymorphous hyperkinesias developed after Nakom administration. The authors assume that dopaminergic substances may play a part in the pathogenesis of some epileptic syndromes, in particular in the period of early ontogenesis of the brain.
Slapal
R
R
Zouhar
A
A
D000547:Amantadine / Q000627:therapeutic use*; D002675:Child, Preschool; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D007980:Levodopa / Q000627:therapeutic use*; D013577:Syndrome
D007980:Levodopa; D000547:Amantadine
Terapeutický efekt dopaminergních substancí u farmakorezistentního Lennox-Gastautova syndromu.